Evobright’s Evobodies trigger a natural immune response in solid tumors

Evobright develops a highly innovative approach to cancer therapy, based on an infection defense mechanism naturally present in the immune system that, in contrast to the artificial approaches commonly used today, promises to be also effective in solid tumors. Pre-clinical data obtained so far show that, by activating an infection marker present on all tumor cells with bispecific antibodies (Evobodies), the marked cells present themselves to γδT cells as bacterially infected, triggering a natural and comprehensive immune response (Chan et al., Front Immunol 2022) that completely eliminates the apparently infected tumor cells.

Based on this concept, Evobright has generated a unique technology platform for the development of multiple drugs against solid tumors. The first Evobody against two cancer indications with high prevalence is currently in pre-clinical development and is planned to be developed until Phase I clinical testing in 2025, then being available for in-licensing / partnering by pharmaceutical companies.

For pharmaceutical companies which already made strategic investments in the CD3/TcE space, the Evobright platform technology offers a possibility to upcycle the tumor anchors from their bispecific TcE molecules into Evobodies and – based on the currently available pre-clinical data – obtain an additional option to achieve their strategic goals in solid tumor treatment. This enables our partners in the pharmaceutical industry to further leverage the strategic investments they have already made in R&D and ClinOps team building.